Skip to content

Sift Biosciences

Plug and Play · Supercharging existing cancer therapies.

Competitors

Adjacent

Also from Plug and Play

All of Plug and Play

Programs

Programs Sift Biosciences went through
ProgramCohortSource
Plug and PlayNot statedPlug and Play Page

About Sift Biosciences

Sift is developing first- and best-in-class T-cell modulators that address a critical unmet need in oncology: most solid tumors lack immunogenic targets and remain resistant to current immunotherapies. Sift differentiates by leveraging molecular mimicry—shared genomic sequences between microbes and humans—to design highly immunogenic cancer antigen variants derived from microorganisms. This novel approach activates an otherwise untapped repertoire of pre-existing memory T-cells originally trained against microbial infections. These microbe-reactive T-cells exhibit more robust functionality compared to conventional cancer-specific T-cells. Building upon our oncology proof-of-concept, Sift is also exploring platform applications to selectively expand target-specific regulatory T cells, with the potential to restore immune tolerance in autoimmune diseases. This dual applicability further highlights the transformative potential of our mimicry-based antigen engineering approach.

Category
Other
Location
United States
Checked
1h ago

Sift Biosciences: questions

Which accelerators did Sift Biosciences go through?

Sift Biosciences is listed by Plug and Play.

Where is Sift Biosciences based?

Sift Biosciences lists United States as its location on Plug and Play's page.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.

New startups by email

Mondays: new YC data, AI and devtools companies and status changes, only when something changed.

Double opt-in. Unsubscribe any time.